[NESTLE] QoQ Annualized Quarter Result on 30-Jun-2011 [#2]

Stock
[NESTLE] NESTLE (M) BHD
Announcement Date
18-Aug-2011
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2011
Quarter
30-Jun-2011 [#2]
Profit Trend
QoQ- -16.57%
YoY- 2.76%
Quarter Report
Latest QR
Upcoming QR
NESTLE's Result
NESTLE's Financial Summary
View:
Show?
Annualized Quarter Result
31/03/12 31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 CAGR
Revenue 4,656,512 4,246,744 4,231,888 4,225,748 4,291,040 4,026,319 4,083,234 9.14%
PBT 827,308 558,809 609,282 637,762 764,428 465,744 560,986 29.53%
Tax -194,988 -131,681 -140,136 -146,686 -175,820 -74,346 -91,468 65.56%
NP 632,320 427,128 469,146 491,076 588,608 391,398 469,518 21.93%
-
NP to SH 632,320 427,128 469,146 491,076 588,608 391,398 469,518 21.93%
-
Tax Rate 23.57% 23.56% 23.00% 23.00% 23.00% 15.96% 16.30% -
Total Cost 4,024,192 3,819,616 3,762,741 3,734,672 3,702,432 3,634,921 3,613,716 7.42%
-
Net Worth 837,164 651,925 468,988 468,989 703,514 614,380 689,411 13.80%
Dividend
31/03/12 31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 CAGR
Div - 422,110 171,962 257,944 - 386,919 156,329 -
Div Payout % - 98.83% 36.65% 52.53% - 98.86% 33.30% -
Equity
31/03/12 31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 CAGR
Net Worth 837,164 651,925 468,988 468,989 703,514 614,380 689,411 13.80%
NOSH 234,500 234,505 234,494 234,494 234,504 234,496 234,493 0.00%
Ratio Analysis
31/03/12 31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 CAGR
NP Margin 13.58% 10.06% 11.09% 11.62% 13.72% 9.72% 11.50% -
ROE 75.53% 65.52% 100.03% 104.71% 83.67% 63.71% 68.10% -
Per Share
31/03/12 31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 CAGR
RPS 1,985.72 1,810.94 1,804.69 1,802.06 1,829.83 1,717.01 1,741.30 9.14%
EPS 269.64 182.14 200.07 209.42 251.00 166.91 200.23 21.92%
DPS 0.00 180.00 73.33 110.00 0.00 165.00 66.67 -
NAPS 3.57 2.78 2.00 2.00 3.00 2.62 2.94 13.80%
Adjusted Per Share Value based on latest NOSH - 234,482
31/03/12 31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 CAGR
RPS 1,985.72 1,810.98 1,804.64 1,802.02 1,829.87 1,716.98 1,741.25 9.14%
EPS 269.64 182.14 200.06 209.41 251.01 166.91 200.22 21.92%
DPS 0.00 180.00 73.33 110.00 0.00 165.00 66.66 -
NAPS 3.57 2.7801 2.00 2.00 3.0001 2.62 2.9399 13.80%
Price Multiplier on Financial Quarter End Date
31/03/12 31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 CAGR
Date 30/03/12 30/12/11 30/09/11 30/06/11 31/03/11 30/12/10 30/09/10 -
Price 56.00 56.20 47.98 47.20 46.80 43.34 42.00 -
P/RPS 2.82 3.10 2.66 2.62 2.56 2.52 2.41 11.03%
P/EPS 20.77 30.86 23.98 22.54 18.65 25.97 20.98 -0.66%
EY 4.82 3.24 4.17 4.44 5.36 3.85 4.77 0.69%
DY 0.00 3.20 1.53 2.33 0.00 3.81 1.59 -
P/NAPS 15.69 20.22 23.99 23.60 15.60 16.54 14.29 6.42%
Price Multiplier on Announcement Date
31/03/12 31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 CAGR
Date 25/04/12 23/02/12 04/11/11 18/08/11 20/04/11 24/02/11 28/10/10 -
Price 55.86 55.80 50.00 47.90 48.00 45.30 43.60 -
P/RPS 2.81 3.08 2.77 2.66 2.62 2.64 2.50 8.09%
P/EPS 20.72 30.64 24.99 22.87 19.12 27.14 21.78 -3.26%
EY 4.83 3.26 4.00 4.37 5.23 3.68 4.59 3.45%
DY 0.00 3.23 1.47 2.30 0.00 3.64 1.53 -
P/NAPS 15.65 20.07 25.00 23.95 16.00 17.29 14.83 3.64%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment